Figures & data
Figure 1. Patient selection flowchart.
1L: first line; BCL2i: B-cell lymphoma-2 inhibitor; BTKi: Bruton’s tyrosine kinase inhibitor; CLL: chronic lymphocytic leukemia; CPT: Current Procedural Terminology; HCPCS: Healthcare Common Procedure Coding System; ICD-9/10-CM: International Classification of Diseases, 9/10th Revision, Clinical Modification; ICD-9/10-PCS: International Classification of Diseases, 9/10th Revision, Procedure Coding System; NDC: National Drug Code; SLL: small lymphocytic lymphoma.
1Diagnosis of CLL was identified using ICD-9-CM code 204.1 and ICD-10-CM code C91.1; diagnosis of SLL was identified using ICD-10-CM code C83.0. Patients with one CLL diagnosis and one SLL diagnosis on different dates were included.
2CLL- or SLL-related anticancer therapies included BTKi, BCL2i, CD20, chemotherapy, chemoimmunotherapy, radiation therapy, chimeric antigen receptor T-cell therapy, and hematopoietic stem cell transplantation and were identified using NDC, HCPCS, CPT, and ICD-9/10-PCS codes.
3BTKi or BCL2i-related malignancies included acute myeloid leukemia, chronic graft versus host disease, CLL/SLL, mantle cell lymphoma, marginal zone lymphoma, and Waldenstrom’s macroglobulinemia and were identified using ICD-9/10-CM codes.
Table 1. Patient demographic and clinical characteristics.
Table 2. 1 L To 3 L treatments observed in the overall data cohort.
Table 3. Sequential targeted therapy by class and by BTKi agent among patients with ≥2 LOTs.
Supplemental Material
Download PDF (120 KB)Data availability statement
The data that support the findings of this study are available from Optum, but restrictions apply to the availability of these data, which were used pursuant to a data use agreement. Data are available from the authors with the permission of Optum.